Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Molecular Partners: Repeats by design

Molecular Partners AG believes the small size, high stability and specificity of its Designed Ankyrin Repeat Proteins can address targets and indications that have yet to be touched by classic monoclonal antibodies, where issues of size, stability and manufacturing capacity can limit their utility.

The company's DARPins are engineered antibody-like molecules that consist of repeat proteins, which themselves are composed of a structural unit of amino acids that is repeated any

Read the full 703 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE